Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 4, 1998, Pages 843-848

  Perkins, Margaret E ^a,b   Wu, Teresa W ^a   Le Blancq, Sylvie M ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ANTIPROTOZOAL AGENT; CYCLOPHILIN; CYCLOSPORIN; CYCLOSPORIN DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PAROMOMYCIN; SDZ 033243; SDZ 205549; SDZ 209313; UNCLASSIFIED DRUG; VALSPODAR;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYPTOSPORIDIUM PARVUM; DRUG DETERMINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; SPOROZOITE;

EID: 0031955903     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.4.843     Document Type: Article

References (33)

1. Bartz, S. R., E. Hohenwalter, M.-K. Hu, D. H. Rich, and M. Malkovsky. 1995. Inhibition of immunodeficiency virus replication by nonimmunosuppressive analogs of cyclosporin A. Proc. Natl. Acad. Sci. USA 92:5381-5385.
2. Bell, A., B. Wernli, and R. M. Franklin. 1994. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506 and rapamycin. Biochem. Pharmacol. 48:495-503.
3. Blagburn, B., and R. Soave. 1997. Prophylaxis and chemotherapy: human and animal, p. 111-128. In R. Fayer (ed.), Cryptosporidium and cryptosporidiosis. CRC Press, Boca Raton, Fla.
4. Blagburn, B. L., C. A. Sundermann, D. S. Linsday, J. E. Hall, and R. R. Tidwell. 1991. Inhibition of Cryptosporidium parvum in neonatal Hsd: (ICR)BR Swiss mice by polyether ionophores and aromatic amidines. Antimicrob. Agents Chemother. 35:1520-1523.
5. Borel, J. F. 1989. Pharmacology of cyclosporin (Sandimmune). Pharmacol. Rev. 41:260-372.
6. Borel, J. F., C. Feurer, H. U. Grubler, and H. Stahlin. 1976. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 6:468-475.
7. Demeule, M., R. M. Wenger, and R. Beliveau. 1997. Molecular interactions of cyclosporin A with P-glycoprotein. J. Biol. Chem. 272:6647-6652.
8. Fayer, R., and R. Fetterer. 1995. Activity of benzimdazoles against cryptosporidiosis in neonatal BALB/c mice. J. Parasitol. 81:794-795.
9. Foote, S. J., J. K. Thompson, A. F. Cowman, and D. J. Kemp. 1989. Amplification of multi-drug resistant phenotype in some chloroquine resistant isolates of P. falciparum. Cell 57:921-930.
10. Ford, J. M. 1996. Experimental reversal of P-glycoprotein-mediated multi-drug resistance by pharmacological chemosensitizers. Eur. J. Cancer 12A: 991-1001.
11. Foxwell, B. M. J., A. Mackie, V. Ling, and B. Hyffel. 1989. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol. Pharmacol. 36:543-546.
12. Gaveriaux, C., D. Boesch, B. Jachez, P. Bollinger, T. Payne, and F. Loor. 1991. SDZ PSC-833, a non-immunosuppressive cyclosporin analog, is a very potent multi-drug resistance modifier. J. Cell Pharmacol. 2:225-234.
13. Germann, U. A. 1996. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur. J. Cancer 32A:927-944.
14. Griffiths, J. K., R. Moore, S. Dooley, G. T. Keusch, and S. Tzipori. 1994. Cryptosporidium parvum infection of Caco-2 cell monolayers induces an apical monolayer defect, selectively increases transmonolayer permeability, and causes epithelial cell death. Infect. Immun. 62:4506-4514.
15. Higgins, C. F. 1992. ABC transporters. Annu. Rev. Cell Biol. 8:67-113.
16. Kocken, C. H. M., A. Van Der Wel, B. Rosenwirth, and A. W. Thomas. 1996. Plasmodium vivax: in vitro antiparasitic effect of cyclosporins. Exp. Parasitol. 84:439-443.
17. Loe, D. W., R. G. Deeley, and S. P. C. Cole. 1996. Biology of the multi-drug resistance associated protein (MRP). Eur. J. Cancer 32A:945-957.
18. Marshall, R., and T. P. Flanigan. 1992. Paromomycin inhibits Cryptosporidium infection of a human enterocyte cell line. J. Infect. Dis. 165:772-774.
19. McDonald, V., R. Stables, D. C. Warhurst, M. R. Barer, D. A. Blewett, H. D. Chapman, G. M. Connolly, P. L. Chiodini, and K. P. W. J. McAdam. 1990. In vitro cultivation of Cryptosporidium parvum and screening for anticryptosporidial drugs. Antimicrob. Agents Chemother. 34:1498-1500.
20. Ouellette, M., K. Lewis, and D. C. Hooper. 1997. Eukaryotic microbial multidrug resistance pumps. ASM News 63:664-667.
21. Page, A. P., S. Kumar, and C. K. S. Carlow. 1995. Parasite cyclophilins and antiparasitic activity of cyclosporin A. Parasitol. Today 11:385-388.
22. Perkins, M. E., S. Volkman, D. F. Wirth, and S. M. Le Blancq. 1997. Characterization of an ATP binding cassette transporter in Cryptosporidium parvum. Mol. Biochem. Parasitol. 87:117-122.
23. Riggs, M. W., A. L. Stone, P. A. Yount, R. C. Langer, M. J. Arrowood, and D. L. Bentley. 1997. Protective monoclonal antibody defines a circumsporozoite-like glycoprotein exoantigen of Cryptosporidium parvum sporozoites and merozoites. J. Immunol. 158:1787-1795.
24. 23a. Riggs, M. W. Personal communication.
25. Sigal, N., F. Dumont, P. Durette, J. J. Sickierka, L. Peterson, D. Rich, B. E. Dunlap, M. Staruch, M. R. Melino, S. L. Koprak, D. Williams, B. Witzel, and J. Pisano. 1991. Is cyclophilin involved in the immunosuppressive and nephrotoxic mechanism of action of cyclosporin A? J. Expt. Med. 173:619-628.
26. Silverman, J. A., M. L. Hayes, B. J. Luft, and K. A. Joiner. 1997. Characterization of the anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive activity and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology. Antimicrob. Agents Chemother. 41:1859-1866.
27. Sterling, C. R., and M. J. Arrowood. 1993. Cryptosporidía, p. 59-225. In J. P. Kreier (ed.), Parasitic protozoa, 2nd ed., vol. 3. Academic Press, New York, N.Y.
28. Twentyman, P. R. 1992. Cyclosporins as drug resistance modifiers. Biochem. Pharmacol. 43:109-117.
29. Twentyman, P. R. 1988. Modification of cytotoxic drug resistance by nonimmunosuppressive cyclosporins. Br. J. Cancer 57:254-258.
30. van Helvoort, A., A. J. Smith, H. Sprong, I. Fritzsche, A. H. Schinkel, P. Borst, and G. van Meer. 1996. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87:507-517.
31. Wenger, R. 1986. Cyclosporine and analogues: structural requirements for immunosuppressive activity. Transplant. Proc. 18:213-218.
32. Wilson, C. M., A. E. Serrano, A. Wasley, A. H. Bogenschutz, A. H. Shanker, and D. F. Wirth. 1989. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science 244:1184-1186.
33. Woods, K. M., M. V. Nesterenko, and S. Upton. 1996. Efficacy of 101 anti-microbials and other agents on the development of Cryptosporidium parvum in vitro. Ann. Trop. Med. Parasitol. 90:603-613.